Commentary|Videos|October 28, 2024
Preclinical CNS Data for Zidesamtinib and Other ROS1 Inhibitors
Author(s)Benjamin Besse, MD, Gregory J. Riely, MD, PhD
Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, discuss preclinical CNS data for the ROS1 inhibitor zidesamtinib.
Advertisement
Episodes in this series
Clinicians referring a patient to MSK can do so by visiting msk.org/refer, emailing referapatient@mskcc.org, or by calling 833-315-2722.
Advertisement
Related to this article
TP53 Comutations, Long-Term Toxicity, and Sunvozertinib Access Shape EGFR+ NSCLC Treatment Decisions
Faculty at an OncLive Scientific Interchange and Workshop discussed factors that help inform treatment selection in advanced EGFR-mutated NSCLC.
The PCR-based OncoMate MSI Dx Analysis System can now identify patients with MSI-H solid tumors who may be eligible for pembrolizumab.
The FDA set a June 25, 2027, target action date for gedatolisib plus fulvestrant in PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer.
Pooled phase 1/2 data support 10 mg/kg every 3 weeks as the provisional pivotal dose of the PD-1/VEGF bispecific antibody cesalatamig in previously treated NSCLC.
The top 5 OncLive TV videos of the week cover insights in NSCLC, gynecologic cancers, CRC, multiple myeloma, and NMIBC.
IL-1β blockade with canakinumab was well tolerated and reduced nodule size in patients with high-risk indeterminate pulmonary nodules.
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
Lung cancer experts outline some of the most crucial findings from ESMO 2026 that could affect future clinical decision-making.
Advertisement
Advertisement
Trending on OncLive
1
FDA Grants Breakthrough Therapy Designation to 64Cu-SAR-bisPSMA for PSMA PET in Biochemically Recurrent Prostate Cancer
2
Detalimogene Responses Improve With Longer Follow-Up in BCG-Unresponsive NMIBC Ahead of BLA Submission
3
Combination Therapy Overcomes Treatment Resistance in Breast Cancer Models
4
Dr Wander on the Evolving First-Line and Post–T-DXd Landscape in HER2+ Metastatic Breast Cancer
5